PRMT7 restricts CD8+ T cells expansion via the NF-κB pathway.
Nivine Srour, Kaixiu Luo, David Allard…·Stéphane Richard
This study identifies PRMT7 as a negative regulator of CD8+ T cell immunity and demonstrates a PROTAC degrader (MS54) that enhances anti-tumor responses by activating the NF-κB pathway.